Although there is insufficient evidence to show a survival benefit of NHT in the high-risk PC population8–10, a strategy of intensive therapy using second-generation androgen receptor axis-targeting agents (ARATs) might be reasonable for high-risk nonmetastatic PC instead of ePLND. The gene discussed is AR; the disease is pachyonychia congenita.